Drug intelligence / Profile preview

CVT12011965

Development stage: Unknown
Lead developer: CVasThera
Modality: Small Molecules
Administration: Oral

Overview

CVT12011965 (also known as CVT120165) is an oral, intestinal-targeted formulation of vorapaxar being developed by CVasThera for the treatment of Crohn's disease. Vorapaxar is a small molecule antagonist of protease-activated receptor-1 (PAR-1). While vorapaxar was originally developed for cardiovascular indications, CVasThera has engineered a specialized galenic formulation designed for localized delivery to the gut mucosa. This formulation features mucus-adhesive properties to promote tissue repair and mucosal healing directly at the site of inflammation in the gastrointestinal tract. The drug has completed Phase I safety assessments and was planned for Phase II pilot studies in Crohn's disease patients.

Other names: vorapaxar formulation

Targets

F2R (Protease-activated receptor 1)

Beyond the preview

Go deeper on CVT12011965.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVT12011965.

Explore the full profile